ClinicalTrials.gg
Status unknownNCT02967887SHINEUpdated Jul 17, 2017

Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC

A Phase 2 interventional study of cisplatin and 5-fluorouracil in Hepatocellular Carcinoma Non-Resectable, sponsored by CbsBioscience. Status unknown at 12 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by CbsBioscience · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing cisplatin in Carcinoma, Hepatocellular — 3 open to participants now, 4 under way, 1 of them phase 3. Cisplatin · Carcinoma, Hepatocellular.

Planned enrollment
7th of 19
96 · median 50
Started
2016
the only one that year
Phase 2
10 of 20
1 open now
Registered
16th of 20
by date
Lead sponsor
1 of 20
CbsBioscience

Among the 20 studies testing cisplatin in Carcinoma, Hepatocellular, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2016, is one of 10 in phase 2, and was the 16th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

3 of the 20 studies testing cisplatin in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing cisplatin in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study is to assess the efficacy and the safety of hepatic arterial infusion of cisplatin and 5-fluorouracil (HAIC) in advanced HCC patients stratified by biomarker expression predicting therapeutic response.

Read the detailed description

Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and 5-fluorouracil has been used in advanced HCC. However, cisplatin or 5-fluorouracil acts on cells without tumor selectivity. Therefore, to improve the tumor selectivity and effectiveness of HAIC, molecular subtyping-based stratification strategies should be considered. In this study, patients who have progressed or intolerance to sorafenib with non-metastatic HCC in TNM stage III-IVA and ECOG PS 0 or 1, Child-Pugh class A will be enrolled. 96 patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times. The primary objective is to determine overall response rate, where benefit is defined as complete or partial response according to mRECIST V1.1. Secondary endpoints include time to progression, progression free survival. The biopsy tissue will be subjected to real time reverse transcriptase polymerase chain reaction for quantification of gene expression levels. Patients will be categorized into two groups according to gene expression results, and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarker for therapeutic response of HAIC.

03

Conditions studied

  • Hepatocellular Carcinoma Non-Resectable
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 20 years old
  • Patients with advanced hepatocellular carcinoma who have progressed or intolerance to Sorafenib
  • Patients with advanced hepatocellular carcinoma who cannot be treated with surgery, transplantation, RFA, or TACE.
  • TNM stage III/IV (including intrahepatic single or multiple tumors without extrahepatic regardless of lymph node metastasis)
  • performance status of 0 or 1
  • Liver function status of Class A or B
  • more than 3 months of
  • serum creatinine \<1.5 mg/dL
  • aminotransferase \<5 times the
  • >1,500 cells/lL
  • count >75,000/lL
  • >10 g/dL

Exclusion criteria

Exclusion Criteria:

  • patients with extrahepatic tumors
  • Patients requiring combined treatment with chemotherapy, radiotherapy, TACE, RFA, or others
  • Patients in any severe and/or uncontrolled medical conditions
  • patients with history of allergic response to CT contrast media
  • patients who participated as subjects in other interventional clinical studies (as of the date of visit) within 60 days before drug administration
  • Any person deemed inappropriate by reason of the investigator for other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    cisplatin and 5-fluorouracil

    Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.

    Drug: cisplatin and 5-fluorouracil

Interventions

  • Drugcisplatin and 5-fluorouracil

    Drug pages: Cisplatin · Fluorouracil

    Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)

    Also known as: CBD-01 and CBD-02

06

What researchers measure

Primary outcomes

  1. Objective tumor response

    Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by radiological review

    Time frame: Approximately 6 months

Secondary outcomes

  1. Time-to-Progression

    Time frame: Approximately 24 months

  2. Progression-free-survival

    Time frame: Approximately 24 months

Other outcomes

  1. Exploratory endpoint: Diagnostic performance of biomarkers

    Patients will be categorized according to the result of biomarker expression and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarkers for therapeutic response of drugs.

    Time frame: Through study completion, an average of 3 months

07

Study locations

3 of 12 sites recruiting
  • Korea University Ansan Hospital
    Ansan, Korea, Republic of
    Not yet recruiting
    • Yim, MD., PhD. · Contact
  • Sooncheonhyang University Hospital Bucheon
    Bucheon, Korea, Republic of
    Not yet recruiting
    • Kim, MD., PhD. · Contact
  • The Catholic University of Korea Bucheon ST. Mary's Hospital
    Bucheon, Korea, Republic of
    Not yet recruiting
    • Lee, MD., PhD. · Contact
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
    Not yet recruiting
    • Chung, MD., PhD. · Contact
  • The Catholic University of Korea Daejeon ST. Mary's Hospital
    Daejeon, Korea, Republic of
    Not yet recruiting
    • Song, MD., PhD. · Contact
  • Chonnam National University Hwasun Hospital
    Hwasun, Korea, Republic of
    Not yet recruiting
    • Cho, MD., PhD. · Contact
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
    Not yet recruiting
    • Seo, MD., PhD. · Contact
  • Seoul National University Hospital
    Seoul, Korea, Republic of
    Not yet recruiting
    • Yoon, MD., PhD. · Contact
  • Sooncheonhyang University Hospital Seoul
    Seoul, Korea, Republic of
    Recruiting
    • Jang, MD., PhD. · Contact
  • The Catholic University of korea, Seoul ST. Mary's Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Si Hyun Bae, MD., PhD. · Contact
  • Ajou University Hospital
    Suwon, Korea, Republic of
    Recruiting
    • Wang, MD., PhD. · Contact
    • Cheong, MD., PhD. · Contact
  • The Catholic University of Korea ST. Vincent's Hospital
    Suwon, Korea, Republic of
    Not yet recruiting
    • Song, MD., PhD. · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Oct 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 18, 2016
Start
Nov 2016
Primary completionEst.
Oct 2018
CompletionEst.
Dec 2018
Last update
Jul 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02967887
Lead sponsor
CbsBioscience
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Nov 2016
Primary completion
Oct 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jul 17, 2017

Study contacts

Jin Young Park
Contact
jonnypark@cbsbio.com
82-2-336-0855
Si Hyun Bae, MD., PhD.
principal investigator · The Catholic University of Korea

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Fluorouracil

Start the discussion